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a b s t r a c t
The chemokine receptor CCR4 has at least two natural agonist ligands, MDC (CCL22) and TARC (CCL17)
which bind to the same orthosteric site with a similar afﬁnity. Both ligands are known to evoke
chemotaxis of CCR4-bearing T cells and also elicit CCR4 receptor internalization. A series of small
molecule allosteric antagonists have been described which displace the agonist ligand, and inhibit
chemotaxis. The aim of this study was to determine which cellular coupling pathways are involved in
internalization, and if antagonists binding to the CCR4 receptor could themselves evoke receptor
internalization. CCL22 binding coupled CCR4 efﬁciently to β-arrestin and stimulated GTPγS binding
however CCL17 did not couple to β-arrestin and only partially stimulated GTPγS binding. CCL22 potently
induced internalization of almost all cell surface CCR4, while CCL17 showed only weak effects. We
describe four small molecule antagonists that were demonstrated to bind to two distinct allosteric sites
on the CCR4 receptor, and while both classes inhibited agonist ligand binding and chemotaxis, one of the
allosteric sites also evoked receptor internalization. Furthermore, we also characterize an N-terminally
truncated version of CCL22 which acts as a competitive antagonist at the orthosteric site, and surprisingly
also evokes receptor internalization without demonstrating any agonist activity. Collectively this study
demonstrates that orthosteric and allosteric antagonists of the CCR4 receptor are capable of evoking
receptor internalization, providing a novel strategy for drug discovery against this class of target.
& 2014 The Authors. Published by Elsevier B.V.
1. Introduction
CCR4 is expressed on a variety of functionally distinct thymo-
cytes including skin-homing T cells (Campbell et al., 1999), CD25þ T
suppressor cells (Iellem et al., 2001) and T helper (Th)2 cells
(Bonecchi et al., 1998), all of which have been shown to migrate
to CCL22 and CCL17 released at sites of inﬂammation. CCR4þ T cells
have been shown to be elevated in several types of allergic disease
(Nouri-Aria et al., 2002; Yang et al., 2004) which increases further
upon allergen challenge (Panina-Bordignon et al., 2001). Taken
together, these ﬁndings have driven interest in CCR4 as a thera-
peutic target for the treatment of inﬂammatory diseases with a Th2
cell component, such as asthma (Gonzalo et al., 1999; Kawasaki
et al., 2001) and atopic dermatitis (Reiss et al., 2001).
Consequently, considerable effort has gone into discovering
small molecule CCR4 antagonists although only one molecule has
made it to human clinical trials to date (Cahn et al., 2013). A subset
of these small molecules have been shown to require intracellular
access for their activity (Purandare and Somerville, 2006), result-
ing in the identiﬁcation of an intracellular allosteric site on the
receptor (referred to as ‘site-2’ in this study) (Andrews et al.,
2008). In the same study, it was apparent that one compound
(BMS-397, referred to as ‘Compound 2’ hereafter) did not bind to
this intracellular allosteric site (Purandare, 2004) but a distinct site
(referred to as ‘site-1’ in this study). Further work (Weston and
Hall, 2008) conﬁrmed that the interactions of these molecules
with CCR4 indicate the presence of two allosteric binding sites on
the receptor, both of which are spatially distinct from the orthos-
teric site to which CCL22 and CCL17 bind. Each of these small
molecules demonstrated the ability to allosterically evoke agonist
dissociation from the orthosteric site, antagonizing cellular func-
tions such as chemotaxis and calcium mobilization. These mole-
cular probes have been used in the present study to demonstrate
biased signaling capacity of CCR4 receptors.
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In addition to evoking chemotaxis, CCR4 ligands have also been
shown to induce receptor internalization from the cell surface of
human Th2 cells, resulting in a loss of functional responsiveness
(Mariani et al., 2004; Sebastiani et al., 2005). GPCR internalization
following agonist exposure is a component of receptor desensiti-
zation, however the role of receptor internalization in regulating
the chemotactic response remains controversial.
In this study we expand the observation that the CCR4 agonists
CCL22 and CCL17 can evoke receptor internalization by exploring
the coupling of the CCR4 receptor to G-proteins and β-arrestin.
Additionally, we conﬁrm the presence of two allosteric binding
sites and demonstrate that small molecules binding to ‘site-1’ are
also capable of evoking receptor internalization while binders of
‘site-2’ do not. Lastly, we also characterize an N-terminally
truncated version of CCL22 (MDC67) which acts as a competitive
antagonist at the orthosteric site, and surprisingly also evokes
receptor internalization without demonstrating any agonist activ-
ity. Based on these biased signaling observations we provide a
novel strategy for drug discovery against this class of chemokine
receptor.
2. Materials and methods
2.1. Reagents
NeuroProbe ChemoTx 3 mm-pore chemotaxis chambers were
purchased from Receptor Technologies Ltd. (Leamington Spa, UK).
Phycoerythrin (PE)-Mouse Anti-Human CCR4 (CD194) mAb, PE
Mouse IgG Isotype control, Fluorescein Isothiocyanate (FITC)
Mouse IgG Isotype Control, Puriﬁed mouse anti-human CD194
were purchased from BD Pharmingen (Beckton Dickenson UK Ltd.,
Oxford, UK). FITC-conjugated anti-human CD4, Alexa-ﬂuor 647
Phalloidin and Alexa-488 conjugated rabbit anti-mouse was pur-
chased from Invitrogen Ltd., (Paisley, UK). [125I]CCL-17 (speciﬁc
activity 2200 Ci/mmol) was obtained from Perkin-Elmer LAS UK
Ltd. (Beaconsﬁeld, UK). [3H]compound 2 and [3H]compound 3
(speciﬁc activity 37 and 53 Ci/mmol respectively) were synthe-
sized by GE Healthcare UK Ltd. (Little Chalfont, UK). The majority
of the chemokines CCL22 and CCL17 were purchased from RandD
Systems Europe Ltd. (Abingdon, UK). Truncated CCL22, (MDC67)
was mostly supplied by Biological Reagents and Assay Develop-
ment (BRandAD), GlaxoSmithKline. Other samples of CCL17 and
MDC67 were purchased from PeproTech (London, UK) while some
CCL22 was supplied by BRandAD, GlaxoSmithKline. In this study
we used a range of protein and small molecule ligands of the CCR4
receptor to probe aspects of its function. Compound 1 and
Compound 2 are representative of a class of lipophilic amines,
and Compound 3 and Compound 4 are representative of a class of
arylsulfonamides (Procopiou et al., 2012), all of which were
synthesized by Respiratory Therapy Area Unit Medicinal Chemis-
try, GlaxoSmithKline (Supplementary data Fig. S1).
2.2. Cell lines
HUT78 cells were obtained from the European Collection of Cell
Cultures (ECACC), Wiltshire, UK. Chinese Hamster Ovary (CHO)
cells were obtained from the ECACC, Wiltshire, UK. CHO cells were
transfected with CCR4 cDNA from human basophils (Power et al.,
1995) in the pCIN4 vector; stable transfectants were selected and
cultured in DMEM (Hams)-F12 media supplemented with 10%
heat-inactivated FBS, 1% L-glutamine and 50 mg/ml G418. Human
Peripheral Blood Mononuclear Cells (PBMCs) were obtained from
the peripheral blood of healthy volunteers using a Percol gradient
according to standard protocol (Ulmer et al., 1983). Acquisition of
the blood samples was approved by Hertfordshire Research Ethics
Committee and all donors gave written informed consent prior to
donation. Prior to use in all experiments, cells were re-suspended
in Assay Buffer [RPMI 1640 supplemented with 1% Bovine Serum
Albumin and 1 mM HEPES].
2.3. Cell culture and membrane preparation
The cells were grown in Corning CellSTACKS© (Corning Inc., NY,
USA) and membrane fragments were prepared from the CHO-
CCR4 cells as previously described (Slack and Hall, 2012).
2.4. Radioligand binding studies
All [125I]-CCL17 and [3H]antagonist radioligand binding experi-
ments were performed using a format previously described (Slack
et al., 2011; Slack and Hall, 2012) but with minor modiﬁcations.
Brieﬂy, antagonist binding assays were carried out in 96-deep well
plates at ambient room temperature (20–22 1C) in binding buffer
(without BSA) with either [3H]compound 2 or [3H]compound 3,
membranes and either vehicle or unlabeled antagonist. Non-
speciﬁc binding (NSB) was determined for [3H]compound 2 and
[3H]compound 3 by 10 μM unlabeled compounds 2 or 3 respec-
tively. Binding was terminated by rapid vacuum ﬁltration through
a 48-well Brandel (Brandel Inc. Gaithersburg, MD, USA) harvester
onto GF/B ﬁlter papers pre-soaked in 0.3% v/v poly-ethylenimine
(for [3H]compound 2) or water (for [3H]compound 3). Samples
were washed rapidly three times with ice cold distilled water and
ﬁlters transferred into liquid scintillation (LS) vials containing 4 ml
LS ﬂuid (Ultima-Flo™ M, Perkin-Elmer LAS UK Ltd., Beaconsﬁeld,
UK). The amount of radioligand bound to receptor was measured
by LS microscopy using a TriCarb 2900TR LS counter (Perkin-Elmer
LAS UK Ltd., Beaconsﬁeld, UK). For saturation binding, CCR4
membranes were incubated with increasing concentrations of
[3H]compound 2 or [3H]compound 3 in the presence of vehicle
or NSB for 2 h prior to ﬁltration.
For competition binding displacement studies, membranes were
mixed with [3H]compound 2 or [3H]compound 3 and increasing
concentrations of unlabeled ligand for 2 h prior to ﬁltration.
2.5. Beta-arrestin assay
The CCR4 cell line was obtained from DiscoveRx and grown in
the manufacturer's suggested medium. Agonist induced coupling
was detected as described (Demont et al., 2011).
2.6. GTPγS assay
CHO-CCR4 cell membranes (5 mg/ml) were mixed at a 1:1 ratio
with 25 mg/ml WGA coupled PS imaging (Leadseeker) beads
(Perkin-Elmer) before being incubated for 1 h at 4 1C. GDP was
added to 384-well solid white plates (Nunc, FAC 4.4 μM) contain-
ing test compound. 35S-GTPγS (Perkin-Elmer) was diluted 1:1200
in assay buffer and 20 μl/well added to the plates before centri-
fugation at 1200 rpm for 30 s. After 3 h plates were read using
Viewlux (Perkin-Elmer) with a 613/55(A09) emission ﬁlter.
2.7. Chemotaxis assay
HUT78 cell chemotaxis was measured using a transwell che-
motaxis chambers. Cells were loaded with 7.5 mg/ml Calcein-AM,
washed and re-suspended in assay buffer [RPMI 1640, 1% BSA,
1 mM HEPES] then incubated at 37 1C for 30 min with vehicle or
antagonist. Chemokines were diluted in assay buffer, loaded into
the lower wells of the chemotaxis chamber and cells (1107
cells/ml) were placed above the ﬁlter and the whole chamber was
incubated at 37 1C for 90 min. After incubation, the ﬁlter was
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removed and washed with 50 ml Dulbecco's Phosphate Buffered
Saline (DPBS). The number of migrated HUT78 cells into the ﬁlter
was measured immediately using a Saﬁre Multiplate Reader
(Tecan, UK).
PBMC T-cell actin polymerization.
The human biological samples were sourced ethically and their
research use was in accord with the terms of the informed
consents. PBMCs were isolated from human blood and stained
with FITC-conjugated anti-human CD4 and PE-conjugated anti-
CCR4 antibodies before incubation with antagonist or vehicle for
30 min at 37 1C. Cells were then incubated with agonist for 15 s.
The assay was terminated by addition of 3% formaldehyde and the
ﬁxed cells stained with Alexa ﬂuor-647 Phalloidin. Data is
expressed as a fraction of the mean ﬂuorescence intensity of
CD4þCCR4þ/CD4þCCR4 cells in the same sample.
2.8. Measurement of cell surface and intracellular CCR4 levels
Cells were re-suspended in assay buffer at a concentration of
1106 cells/ml and incubated with vehicle or antagonist for 30 min at
37 1C. Cells were subsequently incubated with increasing concentra-
tions of CCR4 agonists for 30 min at 37 1C, followed by incubationwith
PE-conjugated anti-CCR4 antibody at 4 1C for 60 min. PBMCs required
additional incubation with FITC-conjugated anti-CD4 antibody to
ensure only CD4þCCR4þ cells are measured. Un-stimulated cells were
incubated with PE Mouse IgG Isotype control to give a basal value. The
assay was terminated by the addition of 3% formaldehyde and CCR4
levels evaluated by ﬂow cytometry on a FACSCanto (BD).
CCR4þCD4þHUT78 cells were identiﬁed by their forward and side-
scatter characteristics and the mean ﬂuorescence intensity of the PE-
CCR4 antibody conjugated cells measured. Receptor internalization
was expressed as a percentage of total receptor surface expression
calculated using control cells incubated with PE-CCR4 (100%) or
matched PE-isotype control (0%). To ensure the calculated internaliza-
tion was not a result of chemokine preventing antibody binding, cells
were chilled to 4 1C and permeabilised with 0.5% Saponin prior to
PE-CCR4 antibody incubation and FACS measurement.
2.9. Confocal microscopy
CHO-CCR4 cells (25,000/ml) were seeded on 13 mm glass cover
slips in the bottom of 12 well plates and left to adhere for 48 h.
Cells were washed 3 times and incubated in serum free media
with or without addition of chemokine (100 nM ﬁnal concentra-
tion) or drug (10µM ﬁnal concentration) for 30 min at 4 1C or 37 1C.
Cover slips were washed 3 times with ice-cold PBS followed by
addition of ice cold ﬁxative (4% PFA in PBS) for 15 min on ice
followed by 15 min at room temperature. Cover slips were blocked
for at least 30 min in PBS/1%FCS or PBS/1%FCS/0.2% Saponin.
Staining with anti-CCR4 antibody (1/100) was performed for 1 h
at room temperature followed by washing 3 times in PBS/1%FCS.
Secondary antibody, rabbit anti-mouse Alexa488 (1/400 in PBS 1%
FCS þ/ saponin) was performed for 1 h at room temperature
followed by washing 3 times in PBS. Coverslips were mounted in
Mowiol 4–88þDAPI and viewed on a Zeiss LSM 5 Pa confocal
microscope. For Transferrin endocytosis studies, 20 μg/ml Alexa-
546 conjugated Transferrin (Invitrogen) and 100 nM MDC were
incubated with CHO-CCR4 cells for 30 min at 4 1C in serum free
medium containing 0.1% Bovine Serum Albumin (BSA). Cells were
washed 3 times in ice cold serum free medium/0.1% BSA then
warmed to 37 1C for 30 min prior to ﬁxation, permeabilisation and
staining with anti-CCR4 as described above.
2.10. Data analysis
Statistical analyses were performed using Graphpad Prism for
Windows, version 5.04 (Graphpad Software, California, USA). All
values are expressed as mean7S.E.M. To determine signiﬁcance
between two groups a Students unpaired t-test was applied. One-
way ANOVA with either post-hoc Dunnett's or Bonferroni Multiple
Comparison Tests were used to compare multiple data sets to
control. P-values o0.05 were considered signiﬁcant. IC50 values
from competition binding displacement curves were converted to
Fig. 1. Radiolabel binding studies reveal three distinct binding sites on the CCR4
receptor. CHO-CCR4 membranes were incubated with radiolabelled CCR4-ligand prior
addition of displacing CCR4-ligands. CCL22 (MDC), MDC67 Compound 1, Compound 2,
Compound 3 and Compound 4 all completely displaced radiolabelled CCL17 (TARC)
(panel A). Compound 3 and Compound 4 completely displaced radiolabelled Com-
pound 3, whereas Compound 1, Compound 2 and CCL22 (MDC) only partially
displaced, and MDC67 had no effect (panel B). Radiolabelled Compound 2 was
displaced completely by Compound 1 and Compound 2, but only partially displaced
by Compound 3, Compound 4 and CCL22 (MDC) and not displaced by MDC67
(panel C). Data shown are the mean7S.E.M of at least three separate determinations.
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inhibition constant (Ki) values using the Cheng–Prusoff
equation (Cheng and Prusoff, 1973). Curve ﬁtting for concentra-
tion–response relationships was achieved using a 4-parameter
logistic equation ﬁt. In Fig. 6 the lower asymptote for TARC and
MDC67 was constrained to the maximal response obtained.
3. Results
3.1. Small molecule antagonists of CCR4 bind to two distinct
allosteric sites
All of the four small molecule antagonists; Compound 1,
Compound 2, Compound 3 and Compound 4 fully inhibited
binding of 125I-CCL17 to CCR4 with pKis of 8.7070.21, 9.10
70.09, 9.0470.17 and 8.7470.09 (n¼8, Fig. 1A). Tritiated ver-
sions of Compound 2 and Compound 3 were synthesized and used
in further radioligand binding studies. Unlabeled Compound 3 and
Compound 4 fully competed binding of tritiated Compound 3,
suggesting they are competitive at the same site (n¼8, Fig. 1B).
Conversely Compound 1, Compound 2 and CCL22 showed only
partial competition and MDC67 showed none, suggesting they
bound different sites on the receptor (n¼8, Fig. 1B). This was
conﬁrmed using radiolabelled Compound 2, where unlabeled
Compound 2 and Compound 1 were fully competitive with
radiolabelled Compound 2, whereas Compound 3, Compound 4
and CCL22 are partial, and MDC67 has no effect (n¼8, Fig. 1C).
3.2. Antagonism of the CCR4 receptor inhibits increases in F-actin
content
CCL17 (Fig. 2A) and CCL22 (Fig. 2B) evoked a concentration-
dependent increase in the cellular F-actin content of CCR4þCD4þ
peripheral blood mononuclear cells (PBMCs) (CCL17 pEC50¼
10.370.25; CCL22 pEC50¼9.970.11, n¼4). Fig. 2A and B shows
that MDC67 evoked a parallel rightward shift in the concentra-
tion–response curve to both CCL17 and CCL22 without reducing
the maximal response (pA2 of MDC67 vs CCL17¼7.4370.04, n¼4;
and vs CCL22 pA2¼7.6570.07, n¼4). Importantly, MDC67 caused
no observable change in cellular F-actin content at concentrations
up to 1 mM exposure (n¼4, Supplementary data Fig. S2). Fig. 2C
and D suggest Compound 2 is an insurmountable antagonist with
a pA2 of 8.070.2 against CCL22, whereas this compound was a
surmountable antagonist for CCL17 (pA2¼8.5670.14, Fig. 2C).
Similarly, as shown in Fig. 2E and F, Compound 4 is an insur-
mountable antagonist of CCL17 (pA2¼8.2170.09) and CCL22
(pA2¼8.0270.21).
3.3. Antagonism of the CCR4 receptor also inhibits cellular
chemotaxis
CCL22 and CCL17 both evoked chemotaxis of HUT78 cells and
generated typical bell-shaped concentration–response curves, and as
a control a 24 h pre-treatment with pertussis toxin (Ptx) completely
Fig. 2. Activation of CCR4 receptors evokes actin polymerization, which is inhibited by antagonists of the CCR4 receptor. Human CD4þCCR4þ T cells were challenged with
CCL22 (MDC) or CCL17 (TARC) for 15 s and increases in the F-actin content were determined as described. Increasing concentrations of MDC67 evoked parallel rightward
shifts in the concentration–response to CCL17 (panel A), and CCL22 (panel B). Compound 2 evoked a rightward shift concentration–response to CCL17 (panel C), and CCL22
(panel D) accompanied with a reduction in the maximal response. Compound 4 also evoked rightward shifts in the concentration–response to CCL17 (panel E), and CCL22
(panel F) accompanied with a reduction in the maximal response.
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abolished chemotaxis (Fig. 3A). The concentration–response peaked
at 1 nM of agonist, after which, chemotaxis declined, hence pEC50's
were calculated using the rising phase only; (pEC50 CCL22¼9.797
0.13, n¼11, pEC50 CCL17¼10.2070.19, n¼5). CCL22 trends to greater
efﬁcacy than CCL17, however results did not reach signiﬁcance
(difference in peak chemotaxis; CCL22¼12.3171.6, n¼11: CCL17¼
8.1471.6, n¼5 respectively, P¼0.13). Importantly, MDC67 displays no
agonist activity in evoking chemotaxis (n¼5), similar to a Ptx treated
control. Compound 2 and Compound 4 induced concentration-
dependent inhibition of the chemotactic response to 1 nM CCL22
(Fig. 3B, pIC50¼8.3170.14, and 8.3870.21, respectively, n¼5).
Although we were unable to use sufﬁciently high concentrations of
MDC67 to produce complete inhibition of chemotaxis, from this
partial inhibition, a pIC50 value of 6.7670.16 (n¼5) was calculated.
3.4. CCR4 receptors couple to G-proteins and β-arrestin
CCL22 induced a concentration-responsive coupling of CCR4 to
β-arrestin, whereas none of the other agents, including CCL17
showed any detectable activity (n¼4, Fig. 4A). Compound 4
(10 mM) could fully antagonize this CCL22-induced coupling of
CCR4 to β-arrestin (n¼4, Fig. 4B). Compound 4 and Compound 2
concentration-dependently inhibited CCL22 (7.2 nM) induced
CCR4 coupling to β-arrestin (pIC50's¼8.970.7; 8.7270.5, n¼16)
whereas MDC67 was not antagonistic in this assay format, and
surprisingly showed some stimulation of CCL22 induced coupling
(n¼4, Fig. 4C).
Both CCL17 and CCL22 induce concentration-dependent
increases in [35S]GTPγS membrane binding, although the max-
imum response to CCL17 was lower than that to CCL22 (n¼4,
Fig. 5A). Conversely, Compounds 2 and 4 and MDC67 were
completely inactive (n¼4, Fig. 5A). Furthermore, MDC67, Com-
pounds 2 and 4 all act as antagonists against CCL22-evoked GTPγS
binding (n¼4, Fig. 5B).
3.5. The orthosteric and one of the allosteric sites are capable of
evoking CCR4 receptor internalization by binding of antagonist
molecules
Conﬁrming previous observations, CCL22 and CCL17 evoked
concentration-dependent reduction in cell surface expression of
CCR4 receptors on HUT78 cells (pEC50's of 8.7770.08 (n¼26) and
7.9870.23 (n¼8) respectively). CCL22 evoked almost complete
receptor internalization and loss of cell surface expression
whereas, CCL17 was markedly less potent and over the concentra-
tion ranges we were able to test approximately 50% of the receptor
remained on the cell surface (Fig. 6A). Although Ptx treatment
completely abolished chemotaxis (Fig. 3A, n¼3) it had no effect on
Fig. 3. Activation of CCR4 induces chemotaxis of HUT78 cells. HUT78 cells were
challenged with CCL22 (MDC) or CCL17 (TARC) in a transwell chemotaxis chamber
system. CCL22 and CCL17 both evoked a concentration-dependent chemotaxis of
HUT78 cells, which was completely inhibited by pretreatment with Pertussis toxin
(Ptx), whereas MDC67 displays no agonist activity (panel A). Compound 2 and
Compound 4 completely inhibit HUT78 cell chemotaxis to 1 nM CCL22, whereas
MDC67 evokes partial inhibition of chemotaxis over the concentration range used
(panel B). Data shown are the mean7S.E.M.
Fig. 4. CCR4 ligands couple differentially to β-arrestin. β-arrestin coupling was
assessed using an enzyme complementation assay. CCL22 induced a concentration–
response coupling of CCR4 to β-arrestin, whereas none of the other tested ligands
showed any activity (panel A). Compound 4 (10 mM) fully antagonized the CCL22-
induced coupling of CCR4 to β-arrestin (panel B). Similarly, concentration–
responses of Compound 4 and Compound 2 fully inhibited CCL22 (7.2 nM) induced
CCR4 coupling to β-arrestin, whereas MDC67 showed some stimulation of coupling
(panel C).
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CCL22 induced receptor internalization. As expected, a CCR8
agonist, I309 had no impact on CCR4 cell surface expression
(n¼8, Fig. 6A).
The lipophilic amines (Compound 1 and Compound 2) which
bind to the ‘site-1’ allosteric site also evoked concentration-
dependent reduction in cell surface expression of CCR4 receptors
(pEC50's of 6.470.2 (n¼4) and 8.070.2 (n¼8) respectively,
Supplementary Table 1) whereas conversely the arylsulfonamides
(Compound 3 and Compound 4), which bind to the second
allosteric site, “site-2”, induced no detectable internalization in
three different cell types (n¼4–5, Supplementary Table 1).
Surprisingly, MDC67, despite being an antagonist of other
responses, also induced receptor internalization equivalent in
amount to CCL17 over the concentration range tested
(pEC50¼7.0170.2, n¼6). Fig. 6B displays the concentration–
response of Compound 2 and MDC67, and the highest concentra-
tion of Compound 4 tested. Fig. 7 shows the comparative CCR4
internalization data for all ligands against HUT78 and also CHO-
CCR4 cells at the highest concentrations tested.
To ensure the apparent internalization was not a result of
chemokine preventing antibody binding, cells were permeabilised
with 0.5% Saponin prior to PE-CCR4 antibody incubation and FACS
measurement to ensure that the total number of receptors
detected per cell was not changed by addition of chemokine
(Supplementary data Fig. S3). In all cell types explored addition
of saponin gives an indication of total cellular CCR4 content, which
was unaffected by 100 nM MDC.
In summary; CCL22 induces close to complete CCR4 internali-
zation and loss of cell surface receptors, whereas CCL17 induces
only partial internalization at the concentrations tested. Similarly,
the competitive orthosteric antagonist MDC67 had a similar
proﬁle to CCL17 while the allosteric ‘site-1’ antagonists clearly
evoke partial internalization, whereas the allosteric ‘site-2’ antago-
nists do not induce internalization.
3.6. The internalization of cell surface CCR4 receptors was conﬁrmed
using confocal microscopy
Fig. 8 shows examples of receptor staining following addition
of 100 nM CCL22 or CCL17 to CHO-CCR4 cells. CCL22 (panel 1) or
CCL17 (panel 3) was incubated with cells at 4 1C for 30 min prior to
ﬁxation or ﬁxation and permeabilisation (panels 5 and 7). Blocking
endocytosis at 4 1C reveals abundant cell surface CCR4 expression
in ﬁne punctate structures on the plasma membrane (panels 1 and
3) and signiﬁcant juxtanuclear intracellular staining when cells are
permeabilised prior to staining with anti-CCR4 antibody (panels
5 and 7). However, incubation of cells with CCL22 at 37 1C for
30 min clearly conﬁrms that almost no CCR4 remains on the cell
surface and all the receptor appears in intracellular vesicular
structures (compare panel 2 with 6).
In comparison incubation of cells with CCL17 at 37 1C for
30 min induced relatively little receptor redistribution from the
plasma membrane to intracellular vesicles (compare panel 4
with 8). Controls slides were processed by omitting the primary
anti-CCR4 antibody or by omitting addition of ligands (Supple-
mentary data Fig. S4).
Fig. 9 shows CHO-CCR4 cells incubated with or without Com-
pound 2 or Compound 4 for 30 min at 37 1C followed by ﬁxation
(panels 1–3) or ﬁxation and permeabilization (panels 4–6). CHO-
CCR4 cells without ligand treatment showed abundant punctate cell
surface expression of CCR4 (panel 1) and some juxtanuclear
Fig. 5. CCR4 ligands couple differently to heterotrimeric G-protein. Membranes
were prepared from CHO-CCR4 cells and 35S-GTPγS binding determined. CCL22
displays full agonist behavior whereas CCL17 is a partial agonist, and Compound 2,
Compound 4 and MDC67 are completely inactive (panel A). MDC67,
Compound 2 and Compound 4 all fully inhibit CCL22-evoked 35S-GTPγS binding
(panel B). Data shown are the mean7S.E.M.
Fig. 6. Agonist and antagonist evoked internalization of cell surface CCR4. Cell
surface levels of CCR4 were determined in HUT78 cells using a PE-conjugated anti-
CCR4 antibody. CCL22 evokes concentration-dependent internalization of HUT78
cell surface CCR4 receptors, which is unaffected by pretreatment with Pertussis
toxin (panel A). CCL17 concentration-dependently evoked partial internalization of
cell surface receptors, whereas the CCR8 agonist CCL1 (100 nM) had no effect
(panel A). The antagonists MDC67 and Compound 2 also evoked partial inter-
nalization of cell surface receptors, whereas Compound 4 had no effect (panel B).
Data shown are the mean7S.E.M.
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intracellular staining following permeabilisation (panel 4). Treat-
ment of cells with Compound 2 resulted in a discernible reduction
in cell surface CCR4 staining (panel 2) and increased intra-
cellular accumulation (panel 5). However treatment of cells with
Compound 4 did not appear to either reduce cell surface expression
of CCR4 or enhance its intracellular accumulation.
The juxtanuclear intracellular staining of internalized CCR4 was
studied by co-incubating CHO-CCR4 cells with 100 nM CCL22 and
Alexa-546 conjugated transferrin. Cells were incubated at 4 1C for
30 min, washed in ice cold media then warmed to 37 1C for 30 min
prior to ﬁxation (Fig. 10). As shown previously, incubation with
CCL22 removed almost all CCR4 from the cell surface (panel 1) and
the receptor appears intracellularly in a juxtanuclear staining
pattern (panel 4) which largely overlaps with the intracellular
accumulation of transferrin (panels 5 and 6). At higher magniﬁca-
tion (panels 7–9) it is clear that this overlap of staining is
substantial, nevertheless it is not complete and there are numer-
ous individual green stained vesicles and red stained vesicles.
4. Discussion
CCR4 is a promising drug target for the treatment of allergic
disorders, however to date only one antagonist has made it to the
clinic (Cahn et al., 2013), and there is a need for novel approaches
to targeting chemokine receptors. In this study we demonstrate
that there are two allosteric binding sites on CCR4, only one of
which evokes receptor internalization. Targeting receptor inter-
nalization rather than conventional allosteric or orthosteric antag-
onism may provide a novel strategy for drug discovery against
chemokine receptors.
Using a panel of CCR4 ligands we ﬁrst characterized them for
receptor binding and functional assays. Using 125I-CCL17 in CCR4
binding studies we conﬁrmed that CCL22 was able to fully
compete binding. We also demonstrated that the N-terminal
truncation of CCL22 is also able to fully compete with 125I-CCL17
binding to CCR4 but with a 66-fold lower afﬁnity than native
CCL22. Moreover, MDC67 clearly acted as a competitive antagonist
in the actin polymerization assay, and inhibited ligand binding,
chemotaxis and GTPγS binding while displaying no agonist activ-
ity in any of these assays.
This was a surprising result as it has previously been suggested
that MDC67 acts as a full agonist for monocyte chemotaxis, and
could evoke HUT78 cell chemotaxis at high concentrations (Pal
et al., 1997; Struyf et al., 1998). In those studies MDC67 did not
induce a Ca2þ response in cells and it also failed to inhibit a CCL22
or CCL17 induced response suggesting a complex mode of action.
Four small molecules were used in the current study to fully
characterize the allosteric binding sites, and all fully inhibited
binding of 125I-CCL17 to CCR4. A competitive ligand will inhibit the
binding of a radioligand to NSB whereas an allosteric antagonist
will inhibit binding to a level dependent on its cooperativity factor
as described (Christopoulos and Kenakin, 2002). Radiolabelled
Compound 3 was only fully displaced by cold Compound 3 and
Compound 4, while radiolabelled Compound 2 was only fully
displaced by cold Compound 2 and Compound 1. Therefore, we
conclude from these binding studies that CCL22, CCL17 and
MDC67 all bind to the same orthosteric site whereas
Compound 4 and Compound 3 bind to a second site, shown
previously to be on the intracellular surface of CCR4 (Andrews
et al., 2008). This study also concludes that Compound 1 and
Compound 2 bind to a third distinct novel allosteric site, support-
ing previous observations (Weston and Hall, 2008).
Using actin polymerization as a functional response to agonist
we showed that Compound 2 and Compound 4 appear as
insurmountable antagonists, consistent with previous observa-
tions (Andrews et al., 2008). Both compounds also fully inhibited
chemotaxis, CCR4 coupling to GTPγS and β-arrestin and were
devoid of agonist activity.
To further our understanding of CCR4 receptor coupling we
studied the effects of the natural ligands on receptor coupling
using a combination of β-arrestin and GTPγS binding. We ﬁrst
examined β-arrestin binding to CCR4 and found CCL22 but not
CCL17 was able to induce coupling. Consistent with their antago-
nist activity, Compound 4 and Compound 2 completely abolished
CCL22 coupling to β-arrestin whereas MDC67 did not block
coupling and indeed may have stimulated it, suggesting a potential
third binding site for this ligand. To quantify heterotrimeric
G protein coupling, we measured GTPγS binding to CHO-CCR4
membranes following ligand stimulation and again found signiﬁ-
cant differences between CCL22 and CCL17. Compound 2 and
Compound 4 were unable to stimulate GTPγS binding and were
able to fully antagonize CCL22 induced coupling, as was MDC67.
These are the ﬁrst studies to show differences in CCL22 and CCL17
coupling to downstream effectors through CCR4.
Having shown that CCL22 and CCL17 are capable of biased
signaling, we examined their effects on receptor internalization. In
our study, CCL22 was able to induce almost complete CCR4 cell surface
downregulation in both cell types examined, with CCL17 only able to
internalize about 50% of cell surface CCR4 over the concentration
Fig. 7. The ability of CCR4 ligands to evoke internalization of cell surface CCR4 is
dependent on their site of binding. Cell surface levels of CCR4 were determined in
HUT78 cells (panel A) and CHO-CCR4 cells (panel B) using a PE-conjugated anti-
CCR4 antibody. Cells were incubated for 30 min with CCR4 agonists CCL22 and
CCL17, and the antagonists MDC67, Compound 1, Compound 2, Compound 3 and
Compound 4, before having cell surface CCR4 levels assessed. One-way ANOVA
with post-hoc Dunnett's Multiple Comparison Test was used to compare data sets
to control; ndenotes Po0.05, nn denotes Po0.01, and nnn denotes Po0.001. Data
shown are the mean7S.E.M.
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ranges we were able to test. Importantly, our confocal microscopy
conﬁrmed the data generated using ﬂow cytometry, and also reveals
ligand induced accumulation of CCR4 in juxtanuclear endosomes that
show a substantial, but not complete, overlap with vesicles containing
endocytosed transferrin. Since CCL22 couples CCR4 to β-arrestin one
would expect endocytosis via clathrin coated pits for which transferrin
endocytosis is a marker.
Careful measurement of the concentration response curves for
the two natural ligands shows that the actin polymerization and
chemotaxis responses are closely concordant with one another
Fig. 9. Localization of CCR4 in CHO-CCR4 cells following antagonist addition. CHO-CCR4 cells were incubated with no addition (panels 1 and 4) or with Compound 2 (panels
2 and 5) or Compound 4 (panels 3 and 6) for 30 min at 37 1C followed by ﬁxation (panels 1–3) or ﬁxation and permeabilisation with 0.2% Saponin (panels 4–6). CCR4 was
stained with anti-CCR4 followed by Alexa488-rabbit anti-mouse antibody, imaged by confocal microscopy and single 0.37 mm optical sections are shown. Scale bar¼20 mm.
Fig. 8. Localization of CCR4 in CHO-CCR4 cells following agonist addition. CHO-CCR4 cells were treated with 100 nM CCL22 (panels 1, 2, 5, and 6) or 100 nM CCL17 (panels 3,
4, 7, and 8) for 30 min at either 4 1C (panels 1, 3, 5, and 7) or 37 1C (panels 2, 4, 6, and 8). Following ﬁxation, cells were left unpermeabilised (panels 1–4) or permeabilised
with 0.2% saponin (panels 5–8). CCR4 was stained with anti-CCR4 followed by Alexa488-rabbit anti-mouse antibody, imaged by confocal microscopy and single 0.37 mm
optical sections are shown. Scale bar¼20 mm.
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and between the two agonists, whereas induction of CCR4 down-
regulation requires a 10 fold higher concentration of CCL22 and a
100 fold higher concentration of CCL17.
The maximal chemotaxis response to CCL22 and CCL17 occurs
at a concentration of 1 nM consequently at this concentration
about 50% of CCR4 will still be on the surface following stimulation
by CCL22 and 100% following stimulation with CCL17. Over the
1 - 10 nM CCL17 concentration range, chemotaxis falls away to almost
zero, whereas there is almost no reduction in cell surface CCR4
expression. Consequently, it is unlikely that receptor downregula-
tion alone is the cause of the cessation of chemotaxis in response
to CCL17. The opposite is true for CCL22 where the CCR4 down-
regulation concentration response curve and the descending
phase of the chemotaxis curve show concordance. Consequently,
“stop-go” responses to CCL22 and CCL17 may be controlled
differently suggesting these chemokines may not have completely
identical or redundant functions.
We conclude from several lines of evidence presented here that
internalization and the chemotactic responses are not necessarily
linked as has been suggested by receptor mutagenesis experiments.
The observation that chemotaxis is completely inhibited by a 24 h
pre-treatment with Ptx whereas endocytosis is not affected at all
also suggests these pathways are coupled independently. Further-
more, the similarity in potency between chemotaxis and actin
polymerization assays and the large separation with potency in
endocytosis further supports the notion of two distinctly coupled
pathways.
Our study also demonstrates that this biased signaling can be
achieved by antagonist molecules binding to one of the two
allosteric sites. Using two distinct small molecule classes of CCR4
antagonists, we have shown that the lipophilic amines (Com-
pounds 1 and 2) which bind allosteric ‘site-1’ appear able to drive
receptor internalization whereas the arylsulphonamides (Com-
pounds 3 and 4) which bind to allosteric ‘site-2’ are not. While
small molecule antagonists for the CCR4 receptor have been
described previously, their ability to evoke receptor internalization
is novel. Recently a novel CCR4 antagonist K777 has been
described which also demonstrated the ability of allosteric
Fig. 10. Localization of CCR4 and endocytosed transferrin. CHO-CCR4 cells were incubated with 100 nM CCL22 and Alexa-546 conjugated Transferrin for 30 min at 4 1C prior
to washing and warming to 37 1C for 30 min. Following ﬁxation and permeabilisation, CCR4 was stained with anti-CCR4 followed by Alexa488-rabbit anti-mouse antibody,
imaged by confocal microscopy and single 0.37 mm optical sections are shown. Scale bar¼20 mm.
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antagonist evoked receptor internalization (Sato et al., 2013).
Collectively these studies provide a unique opportunity for drug
discovery targeting this process, rather than simply relying on the
antagonist's ability to displace the natural agonist molecules.
Having demonstrated that a number of CCR4 antagonists are
able to induce receptor internalization, the next question is how
does this mechanism of antagonism compare with and interact
with the competitive or allosteric effects of these compounds? The
effects of reducing surface receptor density should be similar to
the effects of an irreversible antagonist, since both mechanisms
reduce the number of accessible receptor binding sites for an
agonist, at least on intact cells. However, in assays in broken cell
preparations, such as the [35S]GTPγS binding assay, where receptor
internalization is prevented, an internalizing antagonist would not
have the additional effects discussed below. Hence this mechan-
ism could explain a discrepancy between the effects of an
antagonist in intact vs broken cell preparations. Also, assuming
that internalized receptors are unable to couple to signaling
pathways then receptor internalization will also reduce constitu-
tive signaling and, hence, appear like inverse agonism in intact cell
systems. Using a recently published modiﬁcation of the opera-
tional model of agonist activity (Slack and Hall, 2012; Hall, 2013)
suggests that the contribution of this effect is no greater than a
3-fold shift in the concentration–response curves to the agonists,
but will be dependent on the degree of internalization.
5. Conclusions
In summary, using a panel of agonists or orthosteric and
allosteric antagonists to CCR4 we have been able to reveal biased
functions of this receptor both in terms of β-arrestin coupling and
GTPγS binding and in terms of ligand mediated receptor inter-
nalization. CCL22, CCL17 and MDC67 all competitively bind to the
orthosteric site; Compound 1 and Compound 2 bind to ‘site-1’
which is believed to be extracellular and couples to internalization,
whereas Compound 3 and Compound 4 bind to the second
intracellular ‘site-2’ allosteric site.
Collectively this study demonstrates that orthosteric and allos-
teric antagonists of the CCR4 receptor are capable of evoking
receptor internalization, providing a novel strategy for drug dis-
covery against this class of target.
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